Popular search terms:
Search Results Label
13 results found-
Seqirus | Influenza Expertise
Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.seqirus.com.au/expertise -
CSL Acquires Exclusive Rights to Influenza Treatment
Is a single-dose intravenous treatment for acute uncomplicated influenza, which was developed under contract with the US Government as part of pandemic preparedness efforts.
https://www.seqirus.com.au/-/media/seqirus-australia/news-docs/csl-acquires-exclusive-rights-to-influenza-treatment--news-release-170615.pdf -
Seqirus | A World Leader in Influenza Vaccines
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.seqirus.com.au/ -
Consumer Media Release
Vaccines business formerly owned by Novartis, is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of control of influenza globally.
https://www.seqirus.com.au/-/media/seqirus-australia/news-docs/afluria-quad-2017-consumer-release--seqirus-newsroomfinal.pdf -
Seqirus | Global Manufacturing Network
Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.
https://www.seqirus.com.au/...g/global-manufacturing-network -
Seqirus | Influenza Pandemic Response Solutions
Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
https://www.seqirus.com.au/...za/pandemic-response-solutions -
CSL Acquires Exclusive Rights to Influenza Treatment
CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX).
https://www.seqirus.com.au/...-rights-to-influenza-treatment -
Seqirus | Partnership Opportunities
Seqirus stands with our partners on the front line of public health. We are the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more.
https://www.seqirus.com.au/partnering -
Seqirus | Research & Development Efforts
Seqirus is working tirelessly to optimise our technology and implement transformational long-term approaches to influenza pandemic preparedness.
https://www.seqirus.com.au/r-and-d -
Afluria Quad(tm) - a four strain flu vaccine manufactured in
A quadrivalent flu vaccine manufactured by Seqirus locally in Melbourne, Australia is available for the 2017 Australian flu season for adults aged 18 years and older.
https://www.seqirus.com.au/...-in-australia-is-now-available